论文信息 - EFNA3 is a prognostic biomarker for the overall survival of hepatocellular carcinoma patients. - 字舞流文

EFNA3 is a prognostic biomarker for the overall survival of hepatocellular carcinoma patients.

P. Lin | Hong-tao Yang

[1] I. Ng,et al. Ephrin-A3/EphA2 axis regulates cellular metabolic plasticity to enhance cancer stemness in hypoxic hepatocellular carcinoma. , 2022, Journal of hepatology.

[2] Nan Wang,et al. EFNA3 Is a Prognostic Biomarker Correlated With Immune Cell Infiltration and Immune Checkpoints in Gastric Cancer , 2022, Frontiers in Genetics.

[3] Zhe Zhang,et al. EFNA3 as a predictor of clinical prognosis and immune checkpoint therapy efficacy in patients with lung adenocarcinoma , 2021, Cancer cell international.

[4] Li Ding,et al. Integrated Proteogenomic Characterization of HBV-Related Hepatocellular Carcinoma , 2019, Cell.

[5] Lincoln D Stein,et al. The International Cancer Genome Consortium Data Portal , 2019, Nature Biotechnology.